Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters

Xenobiotica

Volumn 40, Issue 12, 2010, Pages 817-825

  Choi, Min Koo ^a   Jin, Qing Ri ^a   Ahn, Sung Hoon ^b   Bae, Myung Ae ^b   Song, Im Sook ^c  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

AMPK phosphorylation; drug drug interaction; metformin; OCT (organic cation transporter); Sitagliptin

Indexed keywords

METFORMIN; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; ORGANIC CATION TRANSPORTER; SITAGLIPTIN;

ARTICLE; CELL STRAIN; CELL STRAIN HEPG2; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN PHOSPHORYLATION;

ADENYLATE KINASE; ANIMALS; BIOLOGICAL TRANSPORT; DOGS; HEP G2 CELLS; HUMANS; KINETICS; METFORMIN; ORGANIC CATION TRANSPORTER 1; PHOSPHORYLATION; PYRAZINES; TRIAZOLES;

AVENA;

EID: 78249276873     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.520349     Document Type: Article

References (26)

1. Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, Witters LA, Ismail-Beigi F. (2000). Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 380(2):347-352.
2. Ahren B. (2008). Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 4(2):383-394.
3. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH. (2007). Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35(4):525-532.
4. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59(5):1277-1286. (Pubitemid 32385197)
5. Choi MK, Jin QR, Jin HE, Shim CK, Cho DY, Shin JG, Song IS. (2007). Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos 28(9):501-510.
6. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. (2007). Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ter 321(2):673-683.
7. Grant RW, Pirraglia PA, Meigs JB, Singer DE. (2004). Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 164(10):1134-1139.
8. Green J, Feinglos M. (2008). New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 4(4):743-751.
9. Gupta R, Walunj SS, Tokala RK, Parsa K V, Singh SK, Pal M. (2009). Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 10(1):71-87.
10. Herman GA, Bergman A, Yi B, Kipnes M. (2006). Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 22(10):1939-1947. (Pubitemid 44663399)
11. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davis MJ, Ramael S, Gottesdiener KM, Wagner JA. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebocontrolled studies with single oral doses. Clin Pharmacol Ter 78(6):675-688.
12. Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ, Shim CK. (2009). Reduced antidiabetic effect of metformin and downregulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 26(3):549-559.
13. Kao DP, Kohrt HE, Kugler J. (2008). Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25(10):1229-1230.
14. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Tornberry NA, Weber AE. (2005). (2R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a] pyrazin-7 (8H)-yl]-1-(2, 4, 5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48(1):141-151.
15. Kimura N, Okuda M, Inui K. (2005). Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 22(2):255-259.
16. Shin HJ, Lee CH, Park SJ, Shin JG, Song IS. (2010). Establishment and characterization of Mardin-Darby canine kidney cells stably expressing human organic anion transporters. Arch Pharm Res 33(5):709-716.
17. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117(5):1422-1431.
18. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23(5):545-551.
19. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. (1981). Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12(2):235-246.
20. Ullrich KJ, Rumrich G, David C, Fritzsch G. (1993). Bisubstrates: substances that interact with renal contraluminal organic anion and organic cation transport systems. I. Amines, piperidines, piperazines, azepines, pyridines, quinolines, imidazoles, thiazoles, guanidines and hydrazines. Pflugers Arch 425 (3-4): 280-299.
21. Urakami Y, Okuda M, Saito H, Inui K. (2000). Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett 473(2):173-176.
22. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35(4):533-538.
23. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. (2003). Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63(4):844-848.
24. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA. (2004). AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279(46):47898-49905.
25. Zhang L, Schaner ME, Giacomini KM. (1998). Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ter 286(1):354-361. (Pubitemid 28318011)
26. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167-1174.